View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 7, 2016updated 13 Jul 2022 10:15am

SanBio gets Japanese approval for Phase 2 clinical trial for stem cells to treat brain injuries

SanBio has received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) to conduct a Phase 2 clinical trial for using allogeneic stem cells to treat chronic traumatic brain injuries.

SanBio has received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to conduct a Phase 2 clinical trial for using allogeneic stem cells to treat chronic traumatic brain injuries.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The company submitted its clinical trial notification of the regenerative cell therapy (SB623) for traumatic brain injury to PMDA last month.

Claimed to be the first of its kind, the stem cell therapy for traumatic brain injury (STEMTRA) trial will study the safety and efficacy of SB623 cell therapy in treating patients with chronic motor impairments following a traumatic brain injury.

Enrolment for the trial started in the US in October last year, with plans to include clinical trial sites and 52 patients in Japan in order to speed-up the overall enrolment process.

"SB623 has improved outcomes in patients with persistent motor deficits caused by ischemic strokes."

SanBio research head Damien Bates said: "SanBio’s regenerative cell medicine, SB623, has improved outcomes in patients with persistent motor deficits due to ischemic stroke, and our preclinical data suggest it may also help TBI patients."

SB623 cells are modified allogeneic mesenchymal stem cells, derived from bone marrow stromal cells isolated from healthy adult donors. When administered into neural tissue, they support recovery from injury by triggering the brain’s natural regenerative ability.

SanBio recently completed a US-based Phase 1/2a clinical trial for SB623 in patients with chronic motor impairments six months to five years following an ischemic stroke, with results suggesting the medicine’s potential to improve motor function following a stroke.

Based on these results, a Phase 2b randomised double blind clinical trial of 156 subjects began enrolment in December last year.

The company also noted that traumatic brain injuries can result from several causes, such as car crashes, falls, occupational hazards and sports injuries that can lead to lifelong motor deficits. There are currently no approved medicines available for the treatment of persistent motor disability from traumatic brain injury.

Japan had granted marketing approval for regenerative medicines following an amendment to the Pharmaceutical Affairs Law in 2014.

SanBio expects to begin the proposed trial in this year with funds from Mizuho Bank and from a stock listing in April last year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena